Pel–Ebstein fever

Pel–Ebstein fever is a rare type of fever associated with Hodgkin's lymphoma, a type of lymphoma. This fever pattern is characterized by the cyclical occurrence of fever, with the temperature peaking every few days to weeks, followed by a period of normal or below-normal temperatures. The cycle typically repeats itself over a period of 1 to 3 weeks. The exact cause of Pel–Ebstein fever remains unclear, but it is thought to be related to the cyclic release of cytokines or other inflammatory mediators by the tumor cells or the host's immune response to the tumor.

Symptoms and Diagnosis[edit | edit source]

The hallmark of Pel–Ebstein fever is its cyclical pattern. During the febrile phase, patients may experience high temperatures, often accompanied by sweating, chills, and general malaise. When the fever subsides, these symptoms typically resolve, only to recur with the next cycle. This pattern can complicate the diagnosis, as it may mimic other conditions with episodic fevers.

Diagnosis of Pel–Ebstein fever is primarily based on the clinical presentation and the association with Hodgkin's lymphoma. A detailed medical history and physical examination are crucial. Diagnostic tests may include blood tests, imaging studies such as CT scans or MRIs, and a biopsy of the lymph nodes or other affected tissues to confirm the presence of Hodgkin's lymphoma.

Treatment[edit | edit source]

Treatment of Pel–Ebstein fever focuses on addressing the underlying Hodgkin's lymphoma. This may involve a combination of chemotherapy, radiation therapy, and in some cases, stem cell transplantation. The choice of treatment depends on the stage and characteristics of the lymphoma, as well as the patient's overall health.

Management of the fever itself may include the use of antipyretics such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) to provide symptomatic relief. However, controlling the underlying lymphoma is key to resolving the fever.

Prognosis[edit | edit source]

The prognosis for patients with Pel–Ebstein fever largely depends on the stage and aggressiveness of the underlying Hodgkin's lymphoma. Advances in treatment have significantly improved outcomes for many patients. Early diagnosis and appropriate treatment of the lymphoma are critical factors in achieving a favorable prognosis.

Epidemiology[edit | edit source]

Pel–Ebstein fever is a rare phenomenon and is most commonly observed in patients with Hodgkin's lymphoma. The exact prevalence is difficult to determine due to the rarity of the condition and the variability in fever patterns among patients with lymphoma.

History[edit | edit source]

The fever was first described in the late 19th century by Wilhelm Ebstein and Hugo Pel, after whom it is named. Their initial observations noted the peculiar cyclical pattern of fever in patients with Hodgkin's lymphoma, which was distinct from other types of febrile illnesses at the time.